Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
AUSTIN, Texas , Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or th
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
09:48am, Wednesday, 20'th Aug 2025
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
06:45pm, Wednesday, 06'th Aug 2025
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.25 per share a year ago.
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
04:15pm, Wednesday, 06'th Aug 2025
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug.
Keros Therapeutics Reports Second Quarter 2025 Financial Results
04:01pm, Wednesday, 06'th Aug 2025
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 28'th Jul 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS). But which of these two stocks is more att
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
08:00am, Thursday, 17'th Jul 2025
LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
03:12pm, Monday, 09'th Jun 2025
Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas , June 9, 2025 /PRNewswire/ -- ADAR1
Keros Announces Return of $375 Million in Excess Capital to Stockholders
06:55am, Monday, 09'th Jun 2025
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Concludes Strategic Alternatives Review and Provides Update on Development of KER-065
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
04:01pm, Friday, 06'th Jun 2025
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025
BofA says Keros cost reduction 'disappoints,' still sees reasons to like story
01:14pm, Thursday, 29'th May 2025
04 Jun
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
06:55am, Thursday, 29'th May 2025
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeu
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees
01:45pm, Tuesday, 27'th May 2025
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
08:00am, Wednesday, 21'st May 2025
ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas , May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1
